A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma (Q44930012)

7 December 2017

title

A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma (English)

1 reference

7 December 2017

main subject

phase II clinical trial

0 references

1 reference

Charles Erlichman

1 reference

7 December 2017

Jennifer J Knox

1 reference

7 December 2017

Rui Qin

1 reference

7 December 2017

Jonathan R Strosberg

1 reference

7 December 2017

Benjamin Tan

1 reference

7 December 2017

Andreas Kaubisch

1 reference

7 December 2017

Anthony B El-Khoueiry

1 reference

7 December 2017

Tanios S Bekaii-Saab

1 reference

7 December 2017

Steven R Rousey

1 reference

7 December 2017

Helen X Chen

1 reference

7 December 2017

publication date

16 October 2014

1 reference

Investigational New Drugs

7 December 2017

published in

1 reference

7 December 2017

1 reference

7 December 2017

1 reference

7 December 2017

page(s)

241-246

1 reference

Hepatocellular carcinoma: the need for progress.

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Diagnosis and Treatment of Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Opportunities for targeted therapies in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Effect of rapamycin alone and in combination with antiangiogenesis therapy in an orthotopic model of human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0169-3

[Expression of vascular endothelial growth factor correlates with invasion and metastasis of hepatocellular carcinoma]

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25318437

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Rising incidence of hepatocellular carcinoma in the United States

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25318437

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10637-014-0169-3

1 reference

7 December 2017

1 reference